← All claims

Longevity & Aging · Supplements

Do NMN or NR supplements raise a key cell fuel molecule?

The claim, precisely: NAD+ precursors (NMN, NR) increases cellular NAD+

Strong support Longevity & Aging 💰 Industry COI noted
RefutedContestedStrong support
consensus score 0.79

Yes — they reliably raise blood levels in trials, but that is not a proven health benefit.

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

13 support 0 contradict 0 tested null 5 mixed · 18 sources, 12 independent groups

What the evidence shows

NMN/NR supplementation reliably raises blood NAD+ in human RCTs - the best-supported NAD claim (multiple independent groups + meta-analysis).

The evidence (18)

SourceGradeStanceQualityFinding
Ahmadi
2023 · JCI Insight
RCT mixed moderate Crossover RCT in CKD: NR (1000 mg/d) altered NAD-dependent TCA/metabolome but did not improve VO2/work; NAD-pathway engagement without functional gain.
Yi
2023 · GeroScience
RCT supports moderate [FT-verified] FT RCT n=80 dose-resp blood NAD up p<0.001; CAVEAT industry co-sponsored, colorimetric assay
Conze
2019 · Scientific Reports
RCT supports high 8-wk RCT in overweight adults: NR (NIAGEN) dose-dependently increased whole-blood NAD+ ~22-51% vs placebo; well tolerated.
Remie
2020 · Am J Clin Nutr
RCT mixed moderate 6-wk NR in obese humans raised muscle NAD+ metabolites (MeNam) and altered body composition, but several metabolic endpoints null.
Trammell
2016 · Nature Communications
RCT supports high First-in-human: single oral NR dose dose-dependently raised blood NAD+ metabolome up to ~2.7x; landmark oral bioavailability proof.
Pencina
2023 · J Gerontol A
RCT supports moderate MIB-626 microcrystalline NMN significantly increased circulating NAD and its metabolome
Prokopidis
2025 · J Cachexia Sarcopenia Muscle
meta-analysis mixed moderate SR/MA of NMN & NR RCTs: precursors raise NAD+ but no consistent benefit on muscle mass/function; honest "raises NAD+, downstream effects unproven.
Brakedal
2022 · Cell Metabolism
RCT supports high NADPARK: 30-day NR significantly augmented cerebral and blood NAD+ in Parkinson's patients (variable responders); independent group, brain NAD+.
Kuerec
2024 · Mech Ageing Dev
RCT supports moderate Post-hoc of NMN RCT: dose-dependent rise in blood NAD+ across 300-900 mg/d in healthy adults; confirms NMN raises blood NAD+.
Berven
2023 · Nat Commun
RCT supports high NR-SAFE: high-dose NR (3000 mg/d) safely raised whole-blood NAD+ up to ~5-fold in Parkinson's; dose-response confirmation.
Martens
2018 · Nat Commun
RCT supports moderate [FT-verified] FT crossover n=24 NAD+ +60% but p=0.048 one-sided unadj; NAAD more robust; NIAGEN/ChromaDex. Holds
Elhassan
2019 · Cell Rep
RCT supports high 21-day NR in aged men raised skeletal-muscle and blood NAD+ metabolome and lowered inflammatory cytokines; tissue-level NAD+ augmentation.
Shoji
2025 · Aging Cell
RCT supports moderate Crossover RCT: NR raised NAD+ and gave benefits in Werner-syndrome patients; independent confirmation of NR->NAD+ in a clinical population.
Dollerup
2018 · Am J Clin Nutrition
RCT mixed moderate 12-wk NR RCT in obese men: NAD-metabolome shifts but blood NAD+ rise not statistically significant; no insulin-sensitivity benefit (raises-NAD signal weaker here).
Christen
2026 · Nat Metab
RCT mixed high Head-to-head: three NAD precursors differentially raise the NAD+ metabolome in humans; NMN/NR raise NAD+ but compartment/route effects differ.
Chen
2024 · Current Diabetes Reports
meta-analysis supports moderate SR/MA of NMN RCTs: significant elevation of blood NAD+ with NMN, but no robust glucose/lipid benefit; corroborates the NAD+-raising endpoint specifically.
Zhang
2025 · Crit Rev Food Sci Nutr
meta-analysis supports moderate MA (12 RCTs, n=513): NMN significantly elevates blood NAD, but most clinical metabolic outcomes not improved
Yoshino
2021 · Science
RCT supports high NMN RCT in prediabetic women raised muscle NAD+ metabolome and improved muscle insulin sensitivity; independent NMN evidence.

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.